Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02541929 · ClinicalTrials.gov registry record · Phase 2
Fish Oil Brain Delivery Study
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT02541929 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 31 participants.
The verdict
NCT02541929, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
Docosahexaenoic acid (DHA) is an essential omega-3 fish oil. DHA is critical to the structure and function of brain cells. DHA fish oil has been shown to be beneficial in cognition in several animal studies; however, this effect in human studies is not clear. It is not known how much dietary fish oil can get into the human brain. Thus, exploring fish oil delivery in human brains is critical for designing appropriate interventions.
Interventions
- DIETARY_SUPPLEMENT Docosahexaenoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02541929
The ClinicalTrials.gov registry entry for NCT02541929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Docosahexaenoic acid is the first listed.
NCT02541929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02541929 about?
NCT02541929 is a clinical study titled "Fish Oil Brain Delivery Study". Docosahexaenoic acid (DHA) is an essential omega-3 fish oil. DHA is critical to the structure and function of brain cells. DHA fish oil has been shown to be beneficial in cognition in several animal studies; however, this effect in human studies is not clear. It is not known how much dietary fish o...
What is the current status of trial NCT02541929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2016-06-30. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT02541929?
The interventions under investigation include: Docosahexaenoic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02541929?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.